Not your mom’s pro­bi­ot­ic: GV-backed Evelo teams up with Mayo Clin­ic on mi­cro­bio­me drugs

Google Ven­tures-backed Evelo is join­ing forces with the Mayo Clin­ic to de­vel­op and even­tu­al­ly com­mer­cial­ize a fam­i­ly of gut bugs as med­i­cine.

You read that right. Evelo’s re­search is based on the idea that mi­crobes found in the gut can in­flu­ence bi­o­log­i­cal sys­tems through­out the rest of the body. If true, that means nat­u­ral­ly oc­cur­ring hu­man mi­crobes could po­ten­tial­ly be de­vel­oped as a new class of med­i­cine, the com­pa­ny’s CEO Sim­ba Gill tells me.

“What we have is a new modal­i­ty of med­i­cine that al­lows for oral, safe, con­ve­nient, and high­ly ef­fi­ca­cious drugs,” Gill said. “Sin­gle mi­crobes will act as med­i­cine to treat dis­ease.”

Mayo’s mi­crobes

Evelo calls these med­i­cine-wor­thy bugs “mon­o­clon­al mi­cro­bials,” and they’re not the on­ly ones in­trigued by their po­ten­tial phar­ma­co­log­i­cal us­es. The Mayo Clin­ic has been look­ing in­to this field for sev­er­al years, and re­cent­ly pub­lished da­ta in Cell and Arthri­tis and Rheuma­tol­ogy show­ing that pop­ping pills packed with cer­tain mi­cro­bials could sup­press mul­ti­ple scle­ro­sis and rheuma­toid arthri­tis. Mayo proved that in mice, and now Evelo wants to take the strain in­to the clin­ic.

The deal with Mayo gets Evelo a world­wide ex­clu­sive li­cense to the strains and sur­round­ing IP. The com­pa­ny did not dis­close the fi­nan­cial de­tails of the deal.

“This col­lab­o­ra­tion pro­vides us a new strain and fam­i­ly of mi­crobes backed by strong in­tel­lec­tu­al prop­er­ty,” Gill said. “Mayo has done great foun­da­tion­al work, and now we can rapid­ly take this fam­i­ly of mi­crobes in­to de­vel­op­ment by next year.”

Evelo isn’t di­vulging ex­act­ly which dis­eases it will take on first, but did say they’ll be look­ing in­to in­flam­ma­to­ry and neu­roin­flam­ma­to­ry dis­eases.

Evelo’s ex­ist­ing pipeline

As a com­pa­ny, Evelo emerged in 2016 by com­bin­ing two fledg­ling star­tups in­cu­bat­ed by Flag­ship Pi­o­neer­ing. Backed with $100 mil­lion from in­vestors in­clud­ing GV and Flag­ship, the com­pa­ny has been busy tak­ing on this am­bi­tious task of cre­at­ing a new drug modal­i­ty.

“What we’re do­ing is not straight for­ward,” Gill said. “Most peo­ple look at bal­anc­ing the gut ecosys­tem be­cause that’s the low hang­ing fruit. We went for the com­plex, more chal­leng­ing ap­proach. And that’s why we’re ahead of every­one else in this space.”

The new mi­crobes from Mayo add to Evelo’s ex­ist­ing vil­lage of mi­cro­bial fam­i­lies. The com­pa­ny is eval­u­at­ing how spe­cif­ic mi­crobes might in­flu­ence how the body’s im­mune sys­tem re­sponds to melanoma, re­nal and col­orec­tal can­cer, among oth­er dis­ease ar­eas. Gill was mum on ex­act­ly how many strains and pro­grams are on­go­ing, but said “sev­er­al” would en­ter the clin­ic next year.

The fu­ture of med­i­cine

Joseph Mur­ray

Gill has a rather bold pre­dic­tion that mon­o­clon­al mi­cro­bials will rev­o­lu­tion­ize med­i­cine.

“One of the rea­sons we’re so ex­cit­ed about this space is that — for many, many dif­fer­ent dis­eases — mon­o­clon­al mi­cro­bials could be used in com­bi­na­tion with or even dis­place bi­o­log­ics.”

And Mayo Clin­ic seems to agree.

“Our stud­ies show that hu­man de­rived mi­crobes can be used to treat mul­ti­ple im­muno­log­i­cal dis­eases well be­yond the gut,” said Joseph Mur­ray, pro­fes­sor of med­i­cine at Mayo Clin­ic.

Like the ad­vent of mon­o­clon­al an­ti­bod­ies, Gill be­lieves mon­o­clon­al mi­cro­bials will lead to a new wave of smarter drugs — more ef­fi­ca­cious, less tox­ic, and broad­ly ap­plic­a­ble to sev­er­al dis­ease ar­eas.

“Ef­fi­ca­cy, tox­i­c­i­ty, and con­ve­nience are the key at­trib­ut­es we’re look­ing at,” Gill said.

In those ar­eas so far, Gill said mon­o­clon­al mi­cro­bials’ per­for­mance is “strik­ing” in com­par­i­son to bi­o­log­ics.

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)  

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales 

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

President Trump walks past HHS secretary Alex Azar (Getty Images)

Azar falls in line un­der Trump again. Ex­perts say he's re­in­forc­ing a dark sig­nal sent to the FDA

In the latest incident where Alex Azar has steadfastly taken the side of President Donald Trump over that of the FDA, the HHS secretary was noncommittal this morning when asked if he supports the attempt by his subordinates at the FDA to strengthen guidelines for a vaccine EUA.

Appearing on NBC’s Today Show, the HHS secretary muddied the waters, stating that the guidance that matters is the one that is “actually already out there.”

CDC’s Robert Redfield, NIAID’s Anthony Fauci, Admiral Brett Giroir at HHS, and FDA’s Stephen Hahn prepare to testify at a House hearing on June 23 (Getty)

'Ex­treme­ly po­lit­i­cal' — Trump neuters FDA's at­tempt to strength­en vac­cine EUA

Stephen Hahn went before a Senate committee Wednesday and declared he’s fighting. “Every one of the decisions we have reached has been made by career FDA scientists based on science and data, not politics,” he exclaimed, adding that “FDA will not permit any pressure from anyone to change that. I will fight for science.”

A few hours later, he was undermined by President Donald Trump when a reporter asked if he was okay with stricter vaccine guidelines that the FDA was said to be cooking up. “That has to be approved by the White House. We may or may not approve it. That sounds like a political move,” he decided.

New York governor Andrew Cuomo (AP Images)

An­drew Cuo­mo says New York will un­der­take its own vac­cine re­view process, and wouldn’t rec­om­mend trust­ing the fed­er­al gov­ern­ment

The concerns keep mounting over President Donald Trump’s politicization of the FDA and other federal agencies guiding the development of a safe and effective vaccine. And today, the telegenic New York governor Andrew Cuomo appeared to introduce even more politics into the matter — latest in an ongoing series of incidents that have cast the proudly independent FDA in starkly political terms.

During his daily press conference Cuomo said that the state will review any coronavirus vaccines approved by the federal government, citing a lack of trust of the Trump administration. The announcement comes one day after Trump accused the FDA of making an “extremely political” move in proposing stricter vaccine guidance.

PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

The leading anti-tau antibody has failed its first Phase II testing, casting a shadow on a popular target (just trailing amyloid beta) for Alzheimer’s disease.

Roche and AC Immune are quick to acknowledge disappointment in the topline readout, which suggested that semorinemab did not reduce cognitive decline among patients with early Alzheimer’s disease, who are either just starting to have symptoms or have mild manifestations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

Laura Shawver (Silverback Therapeutics)

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

Months after reeling in a $78 million Series B round, Silverback Therapeutics has hooked an even larger Series C.

The Seattle-based company announced Wednesday that it netted $85 million from a slate of new and previous investors. The quick boost could be a sign that an IPO is on the way.

In an email, Silverback CEO Laura Shawver told me she was “not able to provide any additional comments about Silverback” beyond what was shared in the company’s news release. In the prepared statement, she said the company is at “an important growth phase.”

Covid-19 roundup: Op­er­a­tion Warp Speed's 7th vac­cine is live at­ten­u­at­ed; Small biotech touts big suc­cess where gi­ants have failed

Operation Warp Speed is stacking its vaccine portfolio with a “TBD” new candidate: a live attenuated vaccine that can be administered in a single dose, potentially as an oral formulation rather than an injection.

Sound familiar?

That could be because the unannounced candidate appears to match the profile of an inoculation being developed by Merck, according to Bloomberg, which first reported the development based on a presentation by Moncef Slaoui.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

As has been the trend in 2020, Taysha Gene Therapies has become the latest biotech to make a quick ascent from a small, privately-funded company to enjoying its very own Nasdaq ticker.

The Dallas-based biotech raised $157 million for its IPO after pricing shares at $20 apiece Thursday, the high-point of its expected range. Initially pegging $100 million in financing, Taysha offered a little less than 8 million shares and will trade under the $TSHA symbol.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.

CEO Markus Warmuth (Monte Rosa)

Monte Rosa rakes in $96M Se­ries B as it pre­pares 'mol­e­c­u­lar glue' plat­form for IND-en­abling stud­ies

About four months after completing an extension to its Series A, Monte Rosa Therapeutics is putting its next foot forward with another heap of cash.

The Boston-based biotech is back with $96 million in Series B financing with a goal to get its lead program ready for IND-enabling studies by the end of the year. Though Monte Rosa is keeping its specific target a secret for now, the company has been researching how to utilize its protein degradation technology in breast cancer and non-small cell lung cancer, among other areas.